Medtronic PLC $MDT Shares Sold by Bahl & Gaynor Inc.

Bahl & Gaynor Inc. reduced its holdings in Medtronic PLC (NYSE:MDT) by 1.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 48,009 shares of the medical technology company’s stock after selling 580 shares during the period. Bahl & Gaynor Inc.’s holdings in Medtronic were worth $4,185,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC lifted its position in shares of Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after buying an additional 37,265 shares in the last quarter. PFG Advisors lifted its holdings in Medtronic by 55.0% during the first quarter. PFG Advisors now owns 4,144 shares of the medical technology company’s stock valued at $372,000 after purchasing an additional 1,471 shares in the last quarter. AE Wealth Management LLC lifted its holdings in Medtronic by 7.2% during the first quarter. AE Wealth Management LLC now owns 8,899 shares of the medical technology company’s stock valued at $800,000 after purchasing an additional 597 shares in the last quarter. Journey Strategic Wealth LLC acquired a new stake in shares of Medtronic in the first quarter valued at about $207,000. Finally, Avantax Advisory Services Inc. increased its stake in shares of Medtronic by 12.7% during the first quarter. Avantax Advisory Services Inc. now owns 146,432 shares of the medical technology company’s stock worth $13,158,000 after purchasing an additional 16,535 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Trading Up 1.8%

Shares of Medtronic stock opened at $101.16 on Friday. The stock has a 50 day moving average of $95.04 and a 200 day moving average of $90.94. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. The firm has a market capitalization of $129.76 billion, a price-to-earnings ratio of 27.87, a PEG ratio of 2.42 and a beta of 0.77. Medtronic PLC has a fifty-two week low of $79.29 and a fifty-two week high of $102.59.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. Medtronic’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

MDT has been the topic of several research analyst reports. Citigroup lifted their price objective on Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, October 7th. Leerink Partners set a $120.00 target price on Medtronic and gave the company an “outperform” rating in a research report on Wednesday. Daiwa Capital Markets boosted their price target on Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Sanford C. Bernstein set a $111.00 price objective on Medtronic in a research note on Wednesday. Finally, Morgan Stanley lifted their target price on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and an average price target of $109.72.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director William R. Jellison purchased 2,500 shares of the stock in a transaction dated Monday, August 25th. The shares were purchased at an average price of $92.37 per share, with a total value of $230,925.00. Following the completion of the transaction, the director owned 5,000 shares of the company’s stock, valued at approximately $461,850. This trade represents a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.